Global private investment firm, Bridgewest Group, has established LumaCina business unit under Bridgewest Perth Pharma in Perth, Australia. The newly created business leverages the acclaimed team and production facility recently acquired by US-based Bridgewest Group from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc., plus the addition of newly expanded capabilities, most notably, R & D.

LumaCina will commercialise sterile injectable drugs in global markets and is actively expanding its portfolio through increased production under LumaCina branding.

Jon Kafer has been appointed President of LumaCina. He also serves as Chief Commercial Officer of Bridgewest Perth Pharma Pty Ltd, a subsidiary of Bridgewest Group.

Initially, LumaCina will commercialise a select portfolio of sterile injectable drugs for customers previously served by Pfizer, before Bridgewest Group's acquisition of the Perth facility. LumaCina is investing in technology, equipment, and expanded capabilities including R & D, growing a robust pipeline across its portfolio of essential injectable medications, spanning high potency, blow fill seal and multi format vials.